-
公开(公告)号：US20190298816A1
公开(公告)日：2019-10-03
申请号：US16351995
申请日：2019-03-13
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： John J. ENGELHARDT , Mark J. SELBY , Alan J. KORMAN , Mary Diane FEINGERSH , Brenda L. STEVENS
IPC: A61K39/00 , A61K39/395 , C07K16/28 , A61P35/00
Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.
-
公开(公告)号：US20160347849A1
公开(公告)日：2016-12-01
申请号：US15166114
申请日：2016-05-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Zhehong CAI , Indrani CHAKRABORTY , Marie-Michelle Navarro GARCIA , Thomas D. KEMPE , Alan J. KORMAN , Alexander T. KOZHICH , Hadia LEMAR , Mark MAURER , Christina Maria MILBURN , Michael QUIGLEY , Maria RODRIGUEZ , Xiang SHAO , Mohan SRINIVASAN , Brenda L. STEVENS , Kent THUDIUM , Susan Chien-Szu WONG , Jochem GOKEMEIJER , Xi-Tao WANG , Han CHANG , Christine HUANG , Maria JURE-KUNKEL , Zheng YANG , Yan FENG , Patrick GUIRNALDA , Nils LONBERG , Bryan C. BARNHART , Aaron P. YAMNIUK , Karla A. HENNING , Michelle Minhua HAN , Ming LEI , Liang SCHWEIZER , Sandra V. HATCHER , Arvind RAJPAL , Praveen AANUR , Mark J. SELBY
CPC classification number: C07K16/2878 , A61K39/3955 , A61K2039/505 , A61K2039/507 , A61P35/00 , C07K16/2818 , C07K16/30 , C07K16/3023 , C07K16/3038 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N33/574
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
Abstract translation: 本文提供了结合OX40的抗体或其抗原结合部分。 还提供了这些蛋白质在治疗应用中的用途，例如在癌症的治疗中。 还提供了产生抗体的细胞，编码抗体的重链和/或轻链可变区的多核苷酸，以及包含编码抗体的重链和/或轻链可变区的多核苷酸的载体。
-
公开(公告)号：US20240336695A1
公开(公告)日：2024-10-10
申请号：US18640480
申请日：2024-04-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Bryan C. BARNHART , Brigitte DEVAUX , Aaron P. YAMNIUK , Shannon L. OKADA , Brenda L. STEVENS
CPC classification number: C07K16/2878 , A61P31/12 , A61P35/00 , A61P35/02 , A61P35/04 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/75 , C07K2317/92 , C07K2317/94
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
-
公开(公告)号：US20180237534A1
公开(公告)日：2018-08-23
申请号：US15577375
申请日：2016-05-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Zhehong CAI , Indrani CHAKRABORTY , Marie-Michelle Navarro GARCIA , Thomas D. KEMPE , Alan J. KORMAN , Alexander T. KOZHICH , Hadia LEMAR , Mark MAURER , Christina Maria MILBURN , Michael QUIGLEY , Maria RODRIGUEZ , Xiang SHAO , Mohan SRINIVASAN , Brenda L. STEVENS , Kent THUDIUM , Susan Chien-Szu WONG , Jochem GOKEMEIJER , Xi-Tao WANG , Han CHANG , Christine HUANG , Maria JURE-KUNKEL , Zheng YANG , Yan FENG , Patrick GUIRNALDA , Nils LONBERG , Bryan C. BARNHART , Aaron P. YAMNIUK , Karla A. HENNING , Michelle Minhua HAN , Ming LEI , Liang SCHWEIZER , Sandra V. HATCHER , Arvind RAJPAL , Praveen AANUR , Mark J. SELBY
IPC: C07K16/28 , C07K16/30 , A61K39/395 , G01N33/574 , A61P35/00
CPC classification number: C07K16/2878 , A61K39/3955 , A61K2039/505 , A61K2039/507 , A61P35/00 , C07K16/2818 , C07K16/30 , C07K16/3023 , C07K16/3038 , C07K16/3069 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N33/574 , G01N2333/70514
Abstract: Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.
-
公开(公告)号：US20180142030A1
公开(公告)日：2018-05-24
申请号：US15579450
申请日：2016-06-28
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Bryan C. BARNHART , Brigitte DEVAUX , Aaron P. YAMNIUK , Shannon L. OKADA , Brenda L. STEVENS
CPC classification number: C07K16/2878 , A61K2039/505 , A61P31/12 , A61P35/00 , A61P35/02 , A61P35/04 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/75 , C07K2317/92 , C07K2317/94
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
-
Patent Agency Ranking
公开(公告)号：US20240041995A1
公开(公告)日：2024-02-08
申请号：US18052110
申请日：2022-11-02
Applicant: Bristol-Myers Squibb Company
Inventor： John J. ENGELHARDT , Mark J. SELBY , Alan J. KORMAN , Mary Diane FEINGERSH , Brenda L. STEVENS
IPC: A61K39/00 , C07K16/28 , A61K39/395 , A61P35/00
CPC classification number: A61K39/0011 , C07K16/2896 , A61K39/39558 , C07K16/2818 , A61P35/00 , C07K2317/21 , C07K2317/75 , C07K2317/33 , C07K2317/56 , C07K2317/92 , A61K2039/507 , A61K2039/505 , C07K2317/24
Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.
-
公开(公告)号：US20220324989A1
公开(公告)日：2022-10-13
申请号：US17694890
申请日：2022-03-15
Applicant: Bristol-Myers Squibb Company , CytomX Therapeutics, Inc.
Inventor： Bryan C. BARNHART , Brigitte DEVAUX , Aaron P. YAMNIUK , Shannon L. OKADA , Brenda L. STEVENS , James William WEST
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
-
公开(公告)号：US20210054091A1
公开(公告)日：2021-02-25
申请号：US17091375
申请日：2020-11-06
Applicant: Bristol-Myers Squibb Company
Inventor： Bryan C. BARNHART , Brigitte DEVAUX , Aaron P. YAMNIUK , Shannon L. OKADA , Brenda L. STEVENS
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for FcγRIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
-
公开(公告)号：US20200339700A1
公开(公告)日：2020-10-29
申请号：US16958563
申请日：2018-12-27
Applicant: Bristol-Myers Squibb Company , CytomX Therapeutics, Inc.
Inventor： Bryan C. BARNHART , Brigitte DEVAUX , Aaron P. YAMNIUK , Shannon L. OKADA , Brenda L. STEVENS , James William WEST
Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
-
公开(公告)号：US20200030425A1
公开(公告)日：2020-01-30
申请号：US16601231
申请日：2019-10-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： John J. ENGELHARDT , Mark J. SELBY , Alan J. KORMAN , Mary Diane FEINGERSH , Brenda L. STEVENS
IPC: A61K39/00 , C07K16/28 , A61P35/00 , A61K39/395
Abstract: The present invention provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies) that bind to human Inducible T Cell COStimulator (ICOS) and exhibit therapeutically desirable functional properties, e.g., the ability to stimulate human ICOS activity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells, and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the antibodies of the invention are also provided. The antibodies of the invention can be used, for example, as an agonist to stimulate or enhance an immune response in a subject, e.g., antigen-specific T cell responses against a tumor or viral antigen. The antibodies of the invention can also be used in combination with other antibodies (e.g., PD-1, PD-L1, and/or CTLA-4 antibodies) to treat, for example, cancer. Accordingly, the antibodies can be used in therapeutic applications and methods to detect ICOS protein.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.025 seconds)
